Index S&P 500 P/E 91.72 EPS (ttm) 2.37 Insider Own 0.09% Shs Outstand 1.77B Perf Week -0.71%
Market Cap 383.72B Forward P/E 13.57 EPS next Y 15.99 Insider Trans -3.38% Shs Float 1.77B Perf Month -1.39%
Enterprise Value 446.83B PEG 0.64 EPS next Q 3.03 Inst Own 74.56% Short Float 1.25% Perf Quarter 2.43%
Income 4.20B P/S 6.27 EPS this Y 43.87% Inst Trans 0.21% Short Ratio 3.49 Perf Half Y 9.35%
Sales 61.16B P/B - EPS next Y 11.17% ROA 1.69% Short Interest 22.04M Perf YTD -4.98%
Book/sh -1.49 P/C 67.66 EPS next 5Y 21.17% ROE 138.53% 52W High 244.81 -11.31% Perf Year 14.18%
Cash/sh 3.21 P/FCF 19.49 EPS past 3/5Y -28.88% -2.63% ROIC 6.96% 52W Low 164.39 32.07% Perf 3Y 49.06%
Dividend Est. 6.82 (3.14%) EV/EBITDA 16.33 Sales past 3/5Y 1.75% 5.95% Gross Margin 83.38% Volatility 3.52% 2.87% Perf 5Y 108.34%
Dividend TTM 6.65 (3.06%) EV/Sales 7.31 EPS Y/Y TTM -53.78% Oper. Margin 33.00% ATR (14) 6.54 Perf 10Y 280.16%
Dividend Ex-Date Jan 16, 2026 Quick Ratio 0.60 Sales Y/Y TTM 8.57% Profit Margin 6.86% RSI (14) 43.39 Recom 1.84
Dividend Gr. 3/5Y 5.21% 6.56% Current Ratio 0.72 EPS Q/Q 5755.80% SMA20 -1.63% Beta 0.34 Target Price 250.71
Payout 279.00% Debt/Eq - Sales Q/Q 10.04% SMA50 -3.29% Rel Volume 2.47 Prev Close 225.66
Employees 55000 LT Debt/Eq - Earnings Feb 04 BMO SMA200 3.80% Avg Volume 6.32M Price 217.11
IPO Dec 10, 2012 Option/Short Yes / Yes EPS/Sales Surpr. 2.15% 1.25% Trades
Volume 15,319,669 Change -3.79%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-08-26 Downgrade Wolfe Research
Outperform → Peer Perform
Jan-07-26 Resumed UBS
Neutral
$240
Dec-10-25 Upgrade HSBC Securities
Hold → Buy
$265
Nov-13-25 Initiated Scotiabank
Sector Outperform
$280
Nov-04-25 Downgrade DZ Bank
Buy → Hold
$237
Oct-14-25 Downgrade Erste Group
Buy → Hold
Oct-01-25 Downgrade HSBC Securities
Buy → Hold
Sep-17-25 Upgrade Berenberg
Hold → Buy
$270
Aug-12-25 Resumed Piper Sandler
Overweight
$231
Aug-07-25 Upgrade Daiwa Securities
Neutral → Outperform
$214
May-14-25 Downgrade Citigroup
Buy → Neutral
$205
Apr-22-25 Initiated Cantor Fitzgerald
Overweight
$210
Dec-10-24 Resumed BofA Securities
Neutral
$191
Dec-05-24 Downgrade Daiwa Securities
Outperform → Neutral
$180
Nov-22-24 Upgrade Leerink Partners
Market Perform → Outperform
$206
Nov-15-24 Initiated Wolfe Research
Outperform
$205
Nov-04-24 Upgrade Argus
Hold → Buy
Oct-17-24 Initiated Bernstein
Mkt Perform
$203
Jun-05-24 Upgrade HSBC Securities
Hold → Buy
$185
May-17-24 Initiated Cantor Fitzgerald
Overweight
$200
Show Previous Ratings
Feb-04-26 10:08PM
05:28PM
(The Wall Street Journal)
04:57PM
(Investor's Business Daily)
04:41PM
04:09PM
(Investor's Business Daily)
04:01PM
Loading…
04:01PM
01:44PM
(Investor's Business Daily)
12:38PM
12:28PM
11:06AM
10:52AM
10:49AM
10:30AM
10:19AM
09:39AM
(The Wall Street Journal)
09:00AM
Loading…
09:00AM
08:34AM
(The Wall Street Journal)
08:31AM
08:18AM
08:05AM
(Associated Press Finance)
08:02AM
07:50AM
07:48AM
05:24AM
04:36AM
(The Wall Street Journal)
04:24AM
Feb-03-26 07:00PM
05:55PM
11:18AM
08:50AM
08:00AM
Loading…
08:00AM
07:55AM
04:34AM
03:01AM
(The Wall Street Journal)
Feb-02-26 10:17PM
07:28PM
06:02PM
(The Wall Street Journal)
02:25PM
11:12AM
10:35AM
10:34AM
08:29AM
04:05AM
02:13AM
(The Wall Street Journal)
Feb-01-26 07:47AM
06:13AM
Jan-31-26 09:35AM
08:31AM
Jan-30-26 04:57PM
(The Wall Street Journal)
03:50PM
12:57PM
10:36AM
09:15AM
08:53AM
Jan-29-26 09:13AM
08:00AM
Jan-28-26 10:32PM
05:45PM
05:02PM
12:07PM
10:00AM
09:48AM
08:00AM
05:51AM
Jan-27-26 02:51PM
10:53AM
08:34AM
02:16AM
Jan-26-26 07:36PM
09:00AM
07:19AM
(Pharmaceutical Technology)
06:01AM
04:05AM
Jan-25-26 02:30PM
(The Wall Street Journal)
Jan-23-26 01:30AM
Jan-22-26 12:03PM
11:05AM
06:05AM
Jan-21-26 07:10AM
Jan-20-26 01:36PM
Jan-19-26 11:37PM
07:30PM
11:07AM
10:31AM
04:05AM
12:50AM
Jan-18-26 07:40AM
Jan-16-26 06:36PM
01:43PM
08:53AM
(Pharmaceutical Technology)
Jan-15-26 05:45PM
04:50PM
10:43AM
08:32AM
08:26AM
Jan-14-26 04:55PM
09:30AM
07:45AM
Jan-13-26 12:57PM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Richard A. Gonzalez Former Director Aug 22 '25 Proposed Sale 210.84 62,755 13,231,264 Aug 22 06:02 PM Richard A. Gonzalez Former Director Aug 21 '25 Proposed Sale 211.04 90,000 18,993,948 Aug 21 06:04 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Aug 12 '25 Option Exercise 54.86 42,370 2,324,418 219,662 Aug 14 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Aug 12 '25 Sale 198.42 42,370 8,407,055 177,292 Aug 14 05:00 PM AZITA SALEKI-GERHARDT Officer Aug 12 '25 Proposed Sale 198.42 42,370 8,407,068 Aug 12 07:22 PM Richard A. Gonzalez Former Director Aug 01 '25 Proposed Sale 195.83 61,500 12,043,268 Aug 08 05:03 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Aug 05 '25 Sale 198.51 13,295 2,639,253 58,247 Aug 07 05:00 PM NICHOLAS DONOGHOE Officer Aug 05 '25 Proposed Sale 198.51 13,299 2,639,966 Aug 05 04:40 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 31 '25 Option Exercise 79.02 25,700 2,030,814 112,066 Apr 02 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 31 '25 Sale 210.08 58,832 12,359,504 53,234 Apr 02 05:00 PM Stewart Jeffrey Ryan Officer Mar 31 '25 Proposed Sale 210.09 58,832 12,359,897 Mar 31 05:30 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Mar 14 '25 Sale 212.34 17,644 3,746,527 11,577 Mar 18 05:00 PM Reents Scott T Officer Mar 14 '25 Proposed Sale 212.35 17,644 3,746,628 Mar 14 04:34 PM GONZALEZ RICHARD A Director Feb 28 '25 Sale 205.11 92,460 18,964,471 395,097 Mar 04 05:00 PM GONZALEZ RICHARD A Director Mar 03 '25 Sale 210.53 6,168 1,298,549 388,929 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Mar 03 '25 Option Exercise 159.88 18,008 2,879,040 22,627 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Mar 03 '25 Sale 210.00 18,008 3,781,680 4,619 Mar 04 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Feb 28 '25 Sale 206.30 9,892 2,040,722 4,619 Mar 04 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 03 '25 Sale 210.45 21,250 4,472,039 6,130 Mar 04 05:00 PM GONZALEZ RICHARD A Officer Mar 03 '25 Proposed Sale 210.53 6,168 1,298,550 Mar 03 05:57 PM PERRY C SIATIS Officer Mar 03 '25 Proposed Sale 210.00 18,008 3,781,680 Mar 03 04:28 PM TIMOTHY RICHMOND Officer Mar 03 '25 Proposed Sale 210.46 21,250 4,472,184 Mar 03 04:08 PM GONZALEZ RICHARD A Officer Feb 28 '25 Proposed Sale 205.11 92,460 18,964,882 Feb 28 05:37 PM Buckbee Kevin K SVP, CONTROLLER Feb 26 '25 Option Exercise 98.48 16,260 1,601,313 28,906 Feb 28 05:00 PM Buckbee Kevin K SVP, CONTROLLER Feb 26 '25 Sale 203.41 18,944 3,853,372 11,496 Feb 28 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Feb 26 '25 Option Exercise 114.36 22,210 2,539,936 66,494 Feb 28 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Feb 26 '25 Sale 202.90 29,917 6,070,036 44,284 Feb 28 05:00 PM PERRY C SIATIS Officer Feb 28 '25 Proposed Sale 206.31 9,892 2,040,790 Feb 28 04:12 PM Buckbee Kevin K Officer Feb 26 '25 Proposed Sale 203.41 18,944 3,853,398 Feb 26 05:47 PM TIMOTHY RICHMOND Officer Feb 26 '25 Proposed Sale 202.90 29,917 6,070,176 Feb 26 04:04 PM Siatis Perry C EVP, GC AND SECRETARY Feb 20 '25 Sale 197.90 5,778 1,143,453 22,381 Feb 24 05:00 PM PERRY C SIATIS Officer Feb 20 '25 Proposed Sale 197.90 5,778 1,143,492 Feb 20 04:10 PM
